ClinicalTrials.gg
CompletedNCT01401517Updated Apr 21, 2020Results posted

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

A Phase 2 interventional study of sodium nitrite in Peripheral Arterial Disease, sponsored by TheraVasc Inc.. Completed at 10 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by TheraVasc Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
201st of 373
55 · median 64
Started
2011
with 24 others
Phase 2
48 of 479
4 open now
Registered
88th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 201st largest by enrollment of the 373 interventional ones that give a count, is one of 25 that started in 2011, is one of 48 in phase 2, and was the 88th registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

Sodium nitrite has been demonstrated to promote new blood vessel growth, speed up wound healing and prevent tissue necrosis in animals. Since patients with PAD experience many of these problems, this study will seek to determine whether this drug, when given orally, could provide the same benefits to patients with PAD.

Read the detailed description

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and a strong predictor of cardiovascular (CV) mortality. The systemic disease of atherosclerosis in these patients results in arterial stenoses in the arteries supplying the muscles of the lower extremities. During exercise, the stenoses limit the ability to increase blood flow, which leads to an oxygen supply/metabolic demand mismatch, a bio-energetic deficit, and subsequent muscle contractile dysfunction. Thus, the primary pathophysiology of PAD is related to the limitation in blood flow and abnormal hemodynamics (reduced tissue perfusion pressure and blood flow) of the lower limbs during exercise. Patients with PAD commonly present with symptoms of intermittent claudication (IC), often described by patients as a cramping, aching, or fatigue sensation in the calf muscles of the legs that occurs during physical activity. Notably, the symptom of claudication pain is due to exercise-induced ischemia in the muscles of the leg, causing a significant limitation of functional exercise capacity and adversely affecting quality of life.

Sodium nitrite is being investigated as a potential new therapy for improving function in patients with PAD. The overall goal of this dose-ranging study is to evaluate the safety, pharmacokinetics, tolerability, and potential biological activity of multiple doses of oral sodium nitrite in patients with PAD. As described above, the primary pathophysiology of PAD is related to the limitation in blood flow of the lower extremities, resulting in limited exercise tolerance and decreased quality of life. PAD is highly prevalent in patients with diabetes, leading to poor outcomes and accelerated disease progression compared with non-diabetic counter-parts. A common feature of both patient groups is endothelial dysfunction, decreased NO bioavailability, and depletion of NO stores, a finding that may be compounded when PAD and diabetic conditions coexist. Sodium nitrite is an inorganic salt that is found and metabolized in vivo. At physiological concentrations, sodium nitrite is known to cause vasodilation, a feature which is enhanced in hypoxic or ischemic environments. The nitrite anion acts a NO reservoir and can be readily converted to active NO by a non-enzymatic reaction with deoxyhemoglobin, making it a unique candidate for potential therapeutic effect in ischemic tissues. Accordingly, this study is designed to assess the safety and tolerability of sodium nitrite as well as the pharmacokinetic and pharmacodynamic relationship of sodium nitrite at two different doses versus placebo. Sodium nitrite's effects on endothelial function, a marker of NO bioactivity, and measures of functional walking capacity will also be assessed.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is between and including 35 and 85 years of age.
  • Subjects must be either male or females , sterilized or using suitable . Suitable birth control must be total abstinence, male partner sterilization or double barrier method paired with using oral contraception, injectable progestogen, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, or intrauterine device (IUD).
  • History of Peripheral Arterial Disease (PAD) confirmed by medical chart or an ankle brachial pressure index at rest ≤0.90.
  • If receiving medical standard treatment for cardiac risk factors, subject must have been on a stable treatment for at least 1 month prior to Screening. Treatments must have not changed significantly in the last month and are not expected to change over the duration of the study.
  • If subjects experience claudication symptoms, subjects must have stable lower extremity symptoms for at least 1 month prior to Screening.
  • Ability to provide written and willingness as documented by a signed informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Non-atherosclerotic PAD.
  • Lower extremity surgical or percutaneous revascularization, evidence of graft failure or other peripheral vascular surgical procedure within last 6 months prior to Screening.
  • Anticipated lower extremity revascularization within the treatment period.
  • Myocardial infarction, unstable angina, cerebrovascular accident or within 3 months prior to Screening.
  • Poorly controlled diabetes (HgA1c > 10.0).
  • Poorly controlled hypertension (systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 100 mmHg) despite therapy.
  • Systolic blood pressure ≤100 mmHg on current medical regimen.
  • to sodium nitrite or related compounds.
  • Renal insufficiency documented as \< 30 mL/minute/1.73 m2.
  • Pregnant or nursing women.
  • \< 6 months.
  • A chronic illness that may increase the risks associated with this study in the opinion of the investigator.
  • Active requiring active anti-neoplastic therapy that will, in the opinion of the investigator, interfere with study treatment or participation.
  • Active infection.
  • CHF Class III or IV.
  • Recent hospitalization (\< 30 days) for acute coronary syndrome, myocardial infarction, congestive heart failure or stroke.
  • Recent (\< 30 days) coronary revascularization.
  • Previously treated with angiogenic factors or stem cell therapy within 1 year prior to Screening.
  • Involvement in another PAD clinical trial within past 1 month prior to Screening.
  • Exposed tendon, muscle or bone or a diagnosis of critical leg ischemia.
  • Previous amputation within 3 months prior to Screening or planned amputation that would limit walking (e.g. small toe is allowed).
  • The subject's ability to perform the 6 minute walk test is limited by symptoms other than claudication.
  • Current diagnosis of alcohol or other substance abuse.
  • History of methemoglobinemia, [met- > 15%].
  • Inability to speak English (due to need to administer standardized English-language questionnaire).
  • Evidence of anemia.
  • History of chronic hemolytic condition, including sickle cell disease.
  • Chronic use of anti-migraine medication such as Imitrex or sumatriptan.
  • Have a positive screen for glucose-6-phosphate dehydrogenase deficiency at screening.
  • Subjects who regularly take the following medications: Allopurinol, PDE-5 inhibitors, sedative tricyclic antidepressants, antihistamines, meperidine and related central nervous system depressants, and nitrates.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Microcrystalline cellulose NF at 60 mg/capsule, BID

    Drug: sodium nitrite

  • Experimental
    40 mg Sodium Nitrite

    40 mg dose, BID

    Drug: sodium nitrite

  • Experimental
    80 mg Sodium Nitrite

    80 mg dose, BID

    Drug: sodium nitrite

Interventions

  • 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.

    Also known as: TV1001

06

What researchers measure

Primary outcomes

  1. Reporting of Adverse Events During 11 Week Treatment Period.

    The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sodium nitrite compared with placebo over a 10 week treatment period. Subjects will be asked to report any adverse events during the trial period, and blood pressure, methemoglobin levels and other blood chemistries will be assessed during the trial period for changes from baseline.

    Time frame: 11 weeks

Secondary outcomes

  1. Assessment of Changes in Brachial Artery Flow-Mediated Dilation (FMD)at 10 Weeks From Baseline

    Demonstrate the pharmacodynamic effect of sodium nitrite on changes in FMD by imaging before investigational product administration and 10 weeks after administration of investigational product but before dose escalation. FMD was measured at baseline and again after 10 weeks of treatment. The value at ten weeks was subtracted from the baseline value. A negative value represents a worsening of FMD while a positive value represents an improvement in FMD.

    Time frame: 10 weeks

  2. Assessment of Changes in Walking Distance.

    Demonstrate the pharmacodynamic effect of sodium nitrite on changes in functional measures of walking distance. The distance a subject can walk in 6 minutes will be measured prior to the first administration of the investigational product and 10 weeks after taking the investigational product but before the dose escalation. Distance walked in 6 minutes was measured at baseline and again after 10 weeks of treatment. The distance walked at ten weeks was subtracted from the baseline distance walked. A negative value represents a worsening of walking distance while a positive value represents an improvement in walking distance.

    Time frame: 10 weeks

  3. Assessment of Improvement of Quality of Life Using the WIQ (Walking Impairment Questionnaire) and SF-36 Questionnaire.

    Demonstrate the pharmacodynamic effect of sodium nitrite on changes in measures of claudication symptoms using Quality of Life questionnaires (WIQ \& RAND SF-36). The WIQ is a disease-specific instrument that measures community-based walking. The questionnaire consists of four subscales (pain severity, distance, speed, and stairs). The SF-36 is a set of 36 questions that the subject provides short answers on concerning general health issues that the subject chooses. Questionnaires were administered at baseline and again after 10 weeks of treatment. Scores from the individual sections were summed and divided by the maximal score for the section to obtain a percent score, ranging from 0 (inability to perform task) to 100 (no difficulty). The scores for each section at ten weeks was subtracted from the baseline scores for each section of the questionnaires. A negative represents declining function, a positive value represents improvement over the study period.

    Time frame: 10 weeks

07

Results

Posted Jul 1, 2014

Participant flow

Participant flow — Overall Study
MilestonePlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
Started181918
Completed151715
Not completed323

Outcome measures

PrimaryReporting of Adverse Events During 11 Week Treatment Period.

The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sodium nitrite compared with placebo over a 10 week treatment period. Subjects will be asked to report any adverse events during the trial period, and blood pressure, methemoglobin levels and other blood chemistries will be assessed during the trial period for changes from baseline.

Time frame:
11 weeks
Reported as:
Number · participants
Reporting of Adverse Events During 11 Week Treatment Period.
participantsPlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
at least 1 AE91214
SAEs200
SecondaryAssessment of Changes in Brachial Artery Flow-Mediated Dilation (FMD)at 10 Weeks From Baseline

Demonstrate the pharmacodynamic effect of sodium nitrite on changes in FMD by imaging before investigational product administration and 10 weeks after administration of investigational product but before dose escalation. FMD was measured at baseline and again after 10 weeks of treatment. The value at ten weeks was subtracted from the baseline value. A negative value represents a worsening of FMD while a positive value represents an improvement in FMD.

Time frame:
10 weeks
Reported as:
Mean · percentage from baseline in FMD
Assessment of Changes in Brachial Artery Flow-Mediated Dilation (FMD)at 10 Weeks From Baseline
percentage from baseline in FMDPlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
Intent to Treat Population-2.41 ± 6.20-0.93 ± 4.580.06 ± 3.15
Per Protocol Population-2.69 ± 6.50-0.69 ± 4.650.50 ± 3.28
SecondaryAssessment of Changes in Walking Distance.

Demonstrate the pharmacodynamic effect of sodium nitrite on changes in functional measures of walking distance. The distance a subject can walk in 6 minutes will be measured prior to the first administration of the investigational product and 10 weeks after taking the investigational product but before the dose escalation. Distance walked in 6 minutes was measured at baseline and again after 10 weeks of treatment. The distance walked at ten weeks was subtracted from the baseline distance walked. A negative value represents a worsening of walking distance while a positive value represents an improvement in walking distance.

Time frame:
10 weeks
Reported as:
Mean · Feet
Assessment of Changes in Walking Distance.
FeetPlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
Assessment of Changes in Walking Distance.7.35 ± 124.6747.39 ± 180.46-28.82 ± 259.59
SecondaryAssessment of Improvement of Quality of Life Using the WIQ (Walking Impairment Questionnaire) and SF-36 Questionnaire.

Demonstrate the pharmacodynamic effect of sodium nitrite on changes in measures of claudication symptoms using Quality of Life questionnaires (WIQ \& RAND SF-36). The WIQ is a disease-specific instrument that measures community-based walking. The questionnaire consists of four subscales (pain severity, distance, speed, and stairs). The SF-36 is a set of 36 questions that the subject provides short answers on concerning general health issues that the subject chooses. Questionnaires were administered at baseline and again after 10 weeks of treatment. Scores from the individual sections were summed and divided by the maximal score for the section to obtain a percent score, ranging from 0 (inability to perform task) to 100 (no difficulty). The scores for each section at ten weeks was subtracted from the baseline scores for each section of the questionnaires. A negative represents declining function, a positive value represents improvement over the study period.

Time frame:
10 weeks
Reported as:
Median · units on a scale
Assessment of Improvement of Quality of Life Using the WIQ (Walking Impairment Questionnaire) and SF-36 Questionnaire.
units on a scalePlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
WIQ: Walking Distance-1.07 (-14.2 to 45.6)2.13 (-70.3 to 63.4)5.05 (-66.5 to 61.8)
WIQ: Walking Speed0.00 (-23.9 to 38.0)6.52 (-17.4 to 51.5)7.07 (-57.6 to 28.3)
WIQ: Stair Climbing0.0 (-41.7 to 45.8)12.5 (-25.0 to 58.3)0.0 (-37.5 to 45.8)
SF-36: Physical Functioning0.0 (-20.0 to 15.0)5.0 (-25.0 to 35.0)0.0 (-35.0 to 30.0)
SF-36: Limitations due to Physcial Health25.0 (-75.0 to 50)0.0 (-75.0 to 100)0.0 (-100.0 to 50)
SF-36: Limitations due to Emotional Health0.0 (-100.0 to 100.0)0.00 (-100.0 to 100.0)0.0 (-100.0 to 66.7)
SF-36: Energy/Fatigue-2.50 (-25.0 to 20.0)0.0 (-25.0 to 65.0)5.0 (-30.0 to 30.0)
SF-36: Emotional Well Being-4.0 (-44.0 to 20.0)2.0 (-24.0 to 48.0)4.0 (-12.0 to 32.0)
SF-36: Social Functioning0.0 (-25.0 to 12.5)0.0 (-25.0 to 62.5)0.0 (-37.5 to 50.0)
SF-36: Pain0.0 (-55.0 to 22.5)12.5 (-12.5 to 55.0)0.0 (-37.5 to 22.5)
SF-36: General Health0.0 (-25.0 to 20.0)7.5 (-15.0 to 25.0)0.0 (-20.0 to 30.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/18 (11.1%)9/18 (50%)
40 mg Sodium Nitrite—0/19 (0%)12/19 (63.2%)
80 mg Sodium Nitrite—0/18 (0%)14/18 (77.8%)
Most frequent serious events
Most frequent serious events
EventPlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
Worsening PADVascular disorders1/180/190/18
GI BleedGastrointestinal disorders1/180/190/18
Most frequent other events
Most frequent other events
EventPlacebo40 mg Sodium Nitrite80 mg Sodium Nitrite
Headaches and dizzinessGeneral disorders0/184/198/18
GI DisordersGastrointestinal disorders4/182/193/18
InvestigationsInvestigations3/181/193/18
Muscoskeletal and Connective TissuesMusculoskeletal and connective tissue disorders2/183/192/18
InfectionsInfections and infestations1/182/191/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo40 mg Sodium Nitrite80 mg Sodium NitriteTotal
Mean64.9 ± 8.9865.3 ± 8.8667.9 ± 9.9966.0 ± 9.21
Age, Categorical
Age, Categorical(Participants)Placebo40 mg Sodium Nitrite80 mg Sodium NitriteTotal
<=18 years0000
Between 18 and 65 years611421
>=65 years1281434
Sex: Female, Male
Sex: Female, Male(Participants)Placebo40 mg Sodium Nitrite80 mg Sodium NitriteTotal
Female54514
Male13151341
Region of Enrollment
Region of Enrollment(participants)Placebo40 mg Sodium Nitrite80 mg Sodium NitriteTotal
United States18191855
08

Study locations

10 sites
  • University of Colorado Denver Health Sciences Center
    Aurora, Colorado 80045, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44106, United States
  • University Hospitals
    Cleveland, Ohio 44106, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt Heart and Vascular Institute
    Nashville, Tennessee 37232, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Mohler ER 3rd, Hiatt WR, Gornik HL, Kevil CG, Quyyumi A, Haynes WG, Annex BH. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Vasc Med. 2014 Feb;19(1):9-17. doi: 10.1177/1358863X13515043. Epub 2013 Dec 20. PubMed 24363302 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2011
First posted
Jul 25, 2011
Start
Jul 2011
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Jul 1, 2014
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01401517
Lead sponsor
TheraVasc Inc.
Responsible party
Sponsor
First posted
Jul 25, 2011
Start date
Jul 2011
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Jul 1, 2014
Last update
Apr 21, 2020

Study contacts

Tony Giordano, Ph.D.
study director · TheraVasc Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Nitrite

Start the discussion